Clinical trials: Grade I Meningioma
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00104936
- Testing
- adjuvant therapy, radiation therapy, stereotactic radiosurgery
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Intracranial Meningioma
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
- Trial name
- MOMENTUM-1 (NCT06955169)
- Testing
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- Where
- 17 sites in United States
- Volunteers
- 130 people
- Sponsor
- RTOG Foundation, Inc.
Meningioma, Brain Tumor
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Intensity Modulated Proton Therapy…
- Trial name
- NCT02693990
- Testing
- Intensity Modulated Proton Therapy (IMPT)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors, Neuroblastoma
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005955
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Lymphoma
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967200
- Testing
- laboratory biomarker analysis, pharmacogenomic studies
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Grade I Meningioma, Adult, Grade II Meningioma, Adult
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent).
- Conditions
- Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
- Trial name
- NCT04659811
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Nancy Ann Oberheim Bush, MD
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Brain and Central Nervous System Tumors, Metastatic Cancer
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
- Trial name
- NCT00002647
- Testing
- verteporfin, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells.
- Trial name
- NCT00003484
- Testing
- carmustine, irinotecan hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Darell D. Bigner, MD, PhD
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Cilengitide in Treating Children With Refractory Primary Brain Tumors
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma
- Trial name
- NCT00063973
- Testing
- cilengitide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
ABT-751 in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00036959
- Testing
- ABT-751
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institutes of Health Clinical Center (CC)